News room
Technophage Reaches Last Patient First Visit in REVERSE 2 Trial for TP-102
We are thrilled to share a major milestone in Technophage’s TP-102 clinical trial – REVERSE 2 – with the Last Patient First Visit (LPFV) now...
Technophage Initiates Phase 1b/2a Clinical Trial of TZ-161 for Acute Spinal Cord Injury
Technophage S.A., a clinical-stage biopharmaceutical company focused on developing innovative therapies for areas of unmet medical need, today...
Technophage has been granted with the ‘COTEC Innovative Status 2025’
Technophage is proud to announce that it has recently been granted with the ‘COTEC Innovative Status 2025’. COTEC Portugal is the main Portuguese...
Celebrating 20 Years of Technophage
Twenty years ago, Technophage started as a small startup at the Institute of Molecular Medicine, with a small adventurous team isolating...
TECHNOPHAGE and PHAXIAM Therapeutics Enter Strategic Collaboration on Individualized Phages Therapies Against Bacteria Responsible For ~70% of the Most Common Severe Resistant Infections
TECHNOPHAGE, a Portuguese company specializing in GMP phage development and PHAXIAM Therapeutics, a biopharmaceutical company developing innovative...